GlassScriptPhysician profile
Alexandra Moench
NPI 1407462492
$6,710.72
in general payments reported to CMS, 2019-2025
34 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $314 · 2023: $1,662 · 2024: $3,105 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,809 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,809.45 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $790.77 | 2022-2025 | |
| Lilly USA, LLC | $656.36 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $574.15 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $501.27 | 2022-2025 | |
| Leo Pharma INC. | $465.34 | 2024-2025 | Adbry |
| Janssen Biotech, INC. | $444.23 | 2023-2025 | Tremfya |
| Pfizer INC. | $442.12 | 2023-2025 | |
| Genzyme Corporation | $396.14 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $367.20 | 2021-2024 | Dupixent, Libtayo |
| Incyte Corporation | $271.18 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $257.51 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $208.48 | 2023-2024 | Zoryve |
| Merz North America, INC. | $183.63 | 2025 | |
| Sun Pharmaceutical Industries INC. | $163.84 | 2022-2025 | Ilumya |
| Almirall LLC | $161.93 | 2024-2025 | Klisyri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $135.03 | 2025 | Daxxify |
| Ucb, INC. | $94.12 | 2021-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $92.00 | 2023 | |
| Dermavant Sciences, INC. | $80.94 | 2022-2024 | Vtama |
| Botanix Sb INC | $52.96 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.11 | 2021-2025 | Cabtreo |
| Galderma Laboratories, L.P. | $44.89 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $33.79 | 2022 | |
| Daiichi Sankyo INC. | $33.66 | 2021 | |
| Viiv Healthcare Company | $32.25 | 2022 | |
| Verrica Pharmaceuticals INC. | $24.53 | 2024 | Ycanth |
| Organon LLC | $23.03 | 2025 | |
| Fidia Pharma USA INC. | $22.94 | 2024 | |
| Epi Health, LLC | $22.80 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.56 | 2022 | |
| Allergan, INC. | $16.87 | 2022 | |
| Vyne Pharmaceuticals INC. | $15.50 | 2021 | |
| Biofrontera INC. | $15.31 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $14.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Moench listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.